Sorafenib in combination with transarterial chemoembolization and bronchial arterial chemoinfusion in the treatment of hepatocellular carcinoma with pulmonary metastasis

Asia-Pacific Journal of Clinical Oncology

Volumn 8, Issue 2, 2012, Pages 156-163

  Duan, Feng ^a   Wang, Mao Qiang ^a   Liu, Feng Yong ^a   Wang, Zhi Jun ^a   Song, Peng ^a   Wang, Yan ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Hepatocellular carcinoma; Interventional radiology; Lung metastasis; Sorafenib; TACE; TAI

Indexed keywords

FLUOROURACIL; GEMCITABINE; MITOMYCIN; OXALIPLATIN; PIRARUBICIN; SORAFENIB;

ADULT; ALOPECIA; ANEMIA; ARTICLE; BRONCHIAL ATERIAL CHEMOINFUSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMOEMBOLIZATION; DIARRHEA; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; BRONCHIAL ARTERIES; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PYRIDINES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84860249359     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2012.01542.x     Document Type: Article

References (21)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533-43.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-7625.
3. Hung H. Treatment modalities for hepatocellular carcinoma. Curr Cancer Drug Targets 2005; 5: 131-38.
4. Llovet JM, Ricci S, Mazzaferro V etal. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
5. Cheng AL, Kang YK, Chen ZD etal. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
6. Yau T, Chan P, Ng KK etal. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer 2009; 115: 428-36.
7. Gallagher DJ, Kemeny N. Metastatic colorectal cancer: from improved survival to potential cure. Oncology 2010; 78: 237-48.
8. Breau RH, Blute ML. Surgery for renal cell carcinoma metastases. Curr Opin Urol 2010; 20: 375-81.
9. Kogure T, Iwasaki T, Ueno Y etal. Complete remission of a case of hepatocellular carcinoma with tumor invasion in inferior vena cava and with pulmonary metastasis successfully treated with repeated arterial infusion chemotherapy. Hepatogastroenterology 2007; 54: 2113-16.
10. Nakanishi M, Umeda Y, Demura Y etal. Effective use of multi-arterial infusion chemotherapy for advanced non-small cell lung cancer patients: four clinical specified cases. Lung Cancer 2007; 55: 241-7.
11. Komada H, Yamamura M, Kawaguchi Y etal. Disappearance of lung metastases from hepatocellular carcinoma following bronchial arterial infusion of CDDP and MMC. Gan to Kagaku Ryoho 1992; 19 (10 Suppl.): 1504-7.
12. Pawlik TM, Reyes DK, Cosgrove D etal. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol 2011; 29: 3960-7.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
14. National Cancer Institute. Common terminology criteria for adverse events (CTCAE) v3.0. 2006 [Cited 2 July 2010]. Available from:
15. Benson AB 3rd, Abrams TA, Ben-Josef E etal. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw 2009; 7: 350-91.
16. Ikai I, Itai Y, Okita K etal. Report of the 15th follow-up survey of primary liver cancer. Hepatol Res 2004; 28: 21-9.
17. Wörns MA, Weinmann A, Schuchmann M etal. Systemic therapies in hepatocellular carcinoma. Dig Dis 2009; 27: 175-88.
18. Giglia JL, Antonia SJ, Berk LB etal. Systemic therapy for advanced hepatocellular carcinoma: past, present, and future. Cancer Control 2010; 17: 120-9.
19. Sergio A, Cristofori C, Cardin R etal. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 2008; 103: 914-21.
20. Mathonnet M, Descottes B, Valleix D etal. Quantitative analysis using ELISA of vascular endothelial growth factor and basic fibroblast growth factor in human colorectal cancer, liver metastasis of colorectal cancer and hepatocellular carcinoma. World J Gastroenterol 2006; 12: 3782-3.
21. Zender L, Kubicka S. Molecular pathogenesis and targeted therapy of hepatocellular carcinoma. Onkologie 2008; 31: 550-5.